Kanāda - angļu - Health Canada

pro doc limitee - valproic acid (divalproex sodium) - tablet (enteric-coated) - 125mg - valproic acid (divalproex sodium) 125mg - miscellaneous anticonvulsants

Kanāda - angļu - Health Canada

pharmascience inc - valproic acid (divalproex sodium) - tablet (enteric-coated) - 125mg - valproic acid (divalproex sodium) 125mg - miscellaneous anticonvulsants

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

contract pharmacy services-pa - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole 40 mg - pantoprazole sodium delayed-release tablets are indicated for: pantoprazole sodium delayed-release tablets are indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis (ee). for those adult patients who have not healed after 8 weeks of treatment, an additional 8 week course of pantoprazole sodium delayed-release tablets may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. pantoprazole sodium delayed-release tablets are indicated for maintenance of healing of ee and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd. controlled studies did not extend beyond 12 months. pantoprazole sodium delayed-release tablets are indicated for the long-term treatment of pathological hypersecretory conditions, including zollinger-ellison syndrome. - pantoprazole sodium delayed-release tablets are contraindicated

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

abbvie inc. - venetoclax (unii: n54aic43pw) (venetoclax - unii:n54aic43pw) - venetoclax 10 mg - venclexta is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll). venclexta is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (aml) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. concomitant use of venclexta with strong cyp3a inhibitors at initiation and during the ramp-up phase is contraindicated in patients with cll/sll due to the potential for increased risk of tumor lysis syndrome [see dosage and administration ( 2.6 ) and drug interactions ( 7.1 )] . risk summary based on findings in animals and its mechanism of action [see clinical pharmacology ( 12.1 )] , venclexta may cause embryo-fetal harm when administered to a pregnant woman. there are no available data on venclexta use in pregnant women to inform a drug-associated risk. administration of venetoclax to pregnant mice during

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

abco welding and industrial supply inc - oxygen (unii: s88tt14065) (oxygen - unii:s88tt14065) - oxygen 995 ml in 1 l

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme ltd - aprepitant - capsule - 125mg

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - simvastatin - oral tablet - 10mg

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme ltd - aprepitant - powder - 125mg

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

qpharma inc - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin tablets are indicated for the treatment of adults (≥ 18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. levofloxacin tablet is indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae . adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1)] . levofloxacin tablet is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible staphylococcus aureus, streptococcus pneumoniae (including multi-drug-resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, haemophilus parainfluenzae, klebsiel

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

telix pharmaceuticals (anz) pty ltd - glu-urea-lys(ahx)-hbed-cc, quantity: 25 microgram - injection, diluent for - excipient ingredients: sodium acetate; hydrochloric acid; water for injections - illuccix, after radiolabelling with ga-68, is a radioactive diagnostic agent indicated for use with positron emission tomography (pet) imaging combined with computerised tomography (ct) in patients with prostate cancer: who are at risk of metastasis and who are suitable for initial definitive therapy; who have suspected recurrence based on elevated serum prostate specific antigen (psa) level.